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Abstract 
 
Purpose: To externally validate a novel prostate cancer (PCa) risk-calculator (RC), based on 
data of the Swiss arm of the European Randomize Study of Screening for Prostate Cancer 
(ERSPC), and to assess whether the RC (ProstateCheck) is superior to the PCPT RC and 
SWOP RC in an independent Swiss cohort. 
Materials and Methods: Data of all men who underwent prostate biopsy in an academic 
tertiary care center between 2004 and 2012 were retrospectively analyzed. The probability of 
having any PCa or high-grade PCa (Gleason score ≥7) upon prostate biopsy was calculated 
using the ProstateCheck-RC. The RC’s performance was assessed using calibration and 
discrimination and additionally compared with the PCPT- and SWOP-RC by decision curve 
analyses.  
Results: Of 1615 men, 401 (25%) were diagnosed with any PCa and 196 (12%) with high-
grade PCa. Our analyses of the ProstateCheck-RC revealed good calibration in the low risk 
range (0 to 0.4) and moderate overestimation in the higher risk range (0.4 to 1) for any and 
high-grade PCa. The AUC for the discrimination of any PCa and high-grade PCa was 0.69 
and 0.72, respectively, which was slightly but significantly higher compared to the PCPT-
RC (0.66 and 0.69, respectively) and SWOP-RC (0.64 and 0.70, respectively). Decision 
analysis taking into account the harms of transrectal ultrasound measurements of prostate 
volume, found little benefit for ProstateCheck-RC, with inferior properties to the PCPT- and 
SWOP-RC.  
Conclusion: Our independent external evaluation revealed moderate performance of the 
ProstateCheck-RC. Its clinical benefit is limited and inferior to the PCPT- and SWOP-RC.  
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Introduction 
Numerous risk calculators (RCs) have been developed to predict prostate cancer (PCa) 
detection on transrectal biopsy.1-4 These multivariable risk-prediction tools have been shown 
to be superior to prediction using prostate-specific antigen (PSA) testing and digital rectal 
examination (DRE) alone.2,5 The use of PCa RCs is increasingly recommended to reduce 
overdiagnosis and eventually overtreatment, which are a result of PSA screening without 
personalized risk assessment.6-8 
Original reports of novel RCs usually show excellent performance.2,9,10 However, in external 
validations RC performance is often less optimistic.11-16 There are multiple reasons for 
differences in RC performance in different settings. Some RCs are based on prospective or 
retrospective analyses from clinical biopsy series2,17 while others are based on data from 
randomized studies.1,4 Therefore, the underlying patient cohorts often do not reflect real-life 
scenarios of individualized screening. Differences in biopsy strategies (e.g. core numbers) or 
tested populations (e.g. ethnic, environmental and geographical) may also account for 
differences in RC performance.  
A regionally developed RC might thus have advantages over RCs that were developed using 
cohorts of different geographical regions or ethnic compositions. However, whether a 
regionally developed RC really performs better is unknown.  
The aim of the present study was to evaluate the performance of a recently launched RC 
(ProstateCheck) developed from data of the Swiss arm of the European Randomized Study 
for Screening of PCa (ERSPC Aarau) in a contemporary independent Swiss cohort.18,19 
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Material and Methods 
All men who underwent a transrectal ultrasound (TRUS)-guided prostate biopsy between 
January 2004 and July 2012 in a Swiss tertiary care academic center were retrospectively 
identified. Exclusion criteria were age <45 years or >75 years, history of a previous positive 
biopsy and serum PSA>50 ng/ml. Men with prior negative biopsies were included. The study 
was approved by the local ethics committee. 
The decision to undergo a prostate biopsy was made in men with a PSA value >2.5ng/ml or 
an abnormal DRE after individual discussion of potential benefits and harms of the procedure. 
Before 2007, either six- or eight-core biopsies and after 2007 only twelve-core biopsies were 
done. Clinical (pre-biopsy PSA value, age, family history, DRE results (suspicious versus 
unsuspicious for PCa) and TRUS-measured prostate volume) and pathological data (diagnosis 
of any PCa and high-grade PCa (defined as Gleason grade ≥7)) were retrieved from electronic 
hospital charts.  
The ProstateCheck-RC is based on data of approximately 5000 men who participated in the 
Swiss arm of the ERSPC.20  
Six different parameters (total PSA, ratio of free to total PSA, age, family history, suspicious 
DRE and prostate volume) can be entered into the RC.  
Depending on the PSA value of a patient, the RC calculates different probabilities: For men 
with a PSA <3.0ng/ml, the RC does not provide the risks at present but gives predictions of 
PCa diagnosis in the future (i.e. after 4, 8 and 12 years) and recommendations for the timing 
of follow-up screening investigations (i.e. 1 year, 2-3 or 6-8 years). For men with a PSA 
≥3ng/ml the RC predicts the current risk of having any PCa and high-grade PCa. 
Recommendations for further urological workup are given according to the calculated risk of 
any PCa. 
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For this study, patients with a PSA value ≥3ng/ml were further analyzed, as the RC only 
predicts current PCa risk when the PSA values is ≥3ng/ml. The probabilities for any PCa and 
high-grade PCa were calculated and compared with the actual biopsy results of the entire 
cohort. 
Risk calculation for our analysis was performed in June 2015 using the ProstateCheck version 
1.2. All parameters except free/total PSA ratio, which was not available in our dataset but 
was also not mandatory for PCa risk prediction, were manually entered into the 
smartphone application for every patient.  
Calibration and discrimination of the RC were evaluated as previously described.16 
Calibration of the RC was analyzed graphically using calibration plots. Furthermore, the 
calibration slope was calculated and calibration-in-the-large was assessed. Discrimination was 
evaluated using receiver-operation characteristic (ROC) curves and the area under the curve 
(AUC) with corresponding 95% confidence intervals (CI). The AUCs of the different RCs 
were compared using the DeLong test.  
To investigate whether the number of biopsy cores taken or a prior negative biopsy had an 
impact on the performance of the RC, sensitivity analyses for patients with 6-8-core biopsies 
versus 12-core biopsies and for biopsy-naïve men versus men who previously had a 
negative biopsy were performed. 
Finally, the ProstateCheck-RC was compared with two well-known RCs: the PCPT-RC 
version 2.0 and the SWOP-RC version 3+DRE/4+DRE.1,9,10 These two RCs have previously 
been validated and compared in our cohort.16 For the SWOP-RC the TRUS volumes of our 
cohort had to be trichotomized (for details see 16). In the present study only patients with a 
PSA value ≥ 3ng/ml were analyzed to allow comparison with the ProstateCheck-RC.  
Decision curve analyses (DCAs) for the prediction of high-grade PCa were performed to 
assess the net benefit of the three different RCs according to different threshold probabilities 
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at which one would consider to perform a biopsy.21 In contrast to the SWOP-RC, which 
includes prostate volume estimation by DRE and the PCPT-RC, which does not include 
prostate volume at all, the ProstateCheck-RC requires prostate volume measured by TRUS. 
The harm of this unpleasant and costly investigation needs to be taken into account when 
evaluating the RC. Net harm, which is subtracted from net benefit, is defined by the reciprocal 
value of the maximum number of TRUS that one would undertake to detect one high-grade 
PCa, if TRUS was perfectly accurate for diagnosis high-grade PCa. In our base case, we made 
the liberal assumption that a clinician would be prepared to subject as many as 50 patients to 
TRUS in order to find one high-grade cancer, but we varied this assumption in sensitivity 
analyses.   
Statistical analyses were performed using the IBM SPSS Statistics version 22 (IBM, Armonk, 
USA) and R programming language and software environment version 3.1.3 (R Foundation 
for Statistical Computing, Vienna, A) with the extension packages of Kundu and colleagues 
for the calibration plots22 and Vickers and colleagues for the DCAs 
(http://www.decisioncurveanalysis.org).21 
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Results 
Of 2304 men 689 (29.9%) were excluded because they were younger than 45 years or older 
than 75 years, had a PSA <3ng/ml or >50ng/ml or had a previous positive biopsy. Baseline 
characteristics and biopsy results of the final cohort (n=1615) are summarized in Table 1. 
Almost all men were of Caucasian descent (99%). Any PCa and high-grade PCa were found 
in 401 men (25%) and 196 men (12%), respectively. 
Analyses for calibration-in-the-large of the ProstateCheck-RC showed a predicted rate of 23% 
for any PCa compared to an actual detection rate of 25%. The predicted rate for high-grade 
PCa (11%) was also comparable to the actual detection rate (12%; Table 2).  
The calibration plots revealed good calibration in the low risk range (0 to 0.4) and moderate 
overestimation in the higher risk range (0.4 to 1) for any and high-grade PCa (Figure 1,2).  
Analyses of the discriminative ability gave an AUC of 0.69 (95%CI=0.67-0.73) for any PCa 
and 0.72 (95%CI=0.69-0.77) for high-grade PCa (Table 2). The AUCs of PSA alone were 
0.58 (95%CI=0.55-0.61) for any PCa and 0.63 (95% CI=0.59-0.67) for high-grade PCa.  
Our sensitivity analysis stratifying by biopsy core number revealed a higher detection rate 
after 12-core biopsies than after 6-8-core biopsies for any PCa (28.4% vs. 18.9%) and high-
grade PCa (17% vs. 6.8%; Supplemental Table1). The RC overestimated the risk for any and 
high-grade PCa in the 6-8-core group. In the 12-core group the prediction of any PCa was 
close to the observed rate but the RC underestimated the risk for high-grade PCa. The AUCs 
were lower in the 12-core group compared to the 6-8-core group for any PCa (0.68 vs. 0.72) 
and high-grade PCa (0.71 vs. 0.79).   
Our second sensitivity analysis revealed a higher detection rate in the biopsy-naïve 
group for any PCa (30.8% vs. 17.4%) and high-grade PCa (16.9% vs. 6.2%; 
Supplemental Table 2). The RC overestimated the risk for any and high-grade PCa in 
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the group of men with a previous negative biopsy. For biopsy-naïve men, the estimates 
were close to the observed proportion.  
For the PCPT- and SWOP-RC the predicted and actual detection rates for any and high-grade 
PCa were similar (Table 2). The calibration slopes of the ProstateCheck- and SWOP-RC were 
comparable for any PCa and somewhat higher for the ProstateCheck-RC for high-grade PCa  
(Table 2). The calibration plots for the PCPT-RC revealed good calibration in the whole 
prediction range for any and high-grade PCa (Supplemental Figures 1a,b). For the SWOP-RC, 
calibration plots revealed reasonable calibration with moderate overestimation for any PCa 
and mild underestimation for high-grade PCa in the higher risk ranges (Supplemental Figures 
2a,b). 
Compared to the ProstateCheck-RC, the AUCs of the PCPT- and SWOP-RCs were lower for 
any PCa (0.66 and 0.64, respectively) and high-grade PCa (0.69 and 0.70 respectively, Table 
2). The AUC for high-grade PCa of the ProstateCheck-RC was significantly superior to 
the PCPT- (P<0.001) and the SWOP-RC (p=0.02).  
The DCAs revealed that the ProstateCheck-RC has limited net benefit and is inferior to the 
PCPT- and SWOP-RC (Figure 3). Even if one would be prepared to subject 100 men to 
TRUS in order to find one high-grade cancer, the ProstateCheck-RC was inferior to the other 
RCs for almost the complete range of threshold probabilities (data not shown).  
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Discussion 
Numerous reasons have been proposed for the limitations of a ‘one size fits all’ RC including 
changes in clinical practice over time and differences in patient population between RC 
development cohorts and tested cohorts.2,11,23-25 In the present study we independently 
evaluated the performance of the ProstateCheck-RC, in a contemporary clinical Swiss cohort. 
The regionally developed ProstateCheck-RC showed fair to moderate performance compared 
to the two validated international SWOP- and PCPT-RCs. However, decision analysis that 
incorporated the harm of TRUS-measured prostate volume demonstrated that the 
ProstateCheck-RC is clearly inferior to the PCPT-RC and SWOP-RC.  
The ProstateCheck-RC was released as application for smartphones or tablet computers in 
December 2014. Its use is subject to payment of a fee for either a limited number of 
calculations (20 calculations for 3.49US$) or unlimited use during a predefined period (e.g. 
twelve months for 19.99US$). As of yet, detailed data on its development and performance in 
the development cohort have not been published. Furthermore, the source code of the RC is 
not available and external validations are lacking. The user of the ProstateCheck-RC is 
informed that the RC was developed based on data of the Swiss arm of the ERSPC, but 
not that he has to pay for a non-validated tool. Missing detail information restricts 
scientific exchange and improvement of this RC. This is in contrast to the two other 
RCs, which are both available online and free-of-charge. Additionally, both RCs have 
been validated among different cohorts because their source code is available.  
It is unique to this RC that it calculates different probabilities depending on the PSA value of 
a patient and gives recommendations for users whether and when further workup should be 
performed. Recommendations for further workup in the PSA group ≥3ng/ml are based on the 
risk of being diagnosed with any PCa. Although the RC calculates the risk of being diagnosed 
with high-grade PCa, this risk is not incorporated into the recommendation for further 
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workup. We believe that a RC should not focus on the detection of low risk disease but 
reliably predict the risk for high-grade disease to prevent unnecessary biopsies and 
overdiagnosis of indolent PCa, which usually should not trigger active treatment but 
surveillance.26,27  
Although the ProstateCheck-RC was developed based on data of a study which was 
performed in a centre in close vicinity to our centre, we did not identify a clinically 
meaningful superiority of this regional RC over the two international RCs. Wide variations of 
PCa incidence have been reported among different countries and regions.28 These variations 
may influence RC performance in different cohorts but are expected to be similar in our 
cohort and the ProstateCheck-RC development cohort. However, there are also important 
differences between the two cohorts. The RC was developed from data of a population-based 
mass screening trial. Men in our cohort were biopsied after individualized screening. The 
underlying biopsy strategy of the RC (6-core biopsy) is different to current recommendations 
for prostate biopsies (e.g. 10-12-core biopsy), which were followed in most patients in our 
cohort. Our sensitivity analysis confirmed an inferior performance of the ProstateCheck-RC 
in the 12-core biopsy group. Furthermore, our cohort, as many clinical cohorts, included a 
notable amount of previously biopsied men. A prior negative biopsy, which has an impact on 
RC performance, as shown in our sensitivity analysis, is a variable of the SWOP-RC and 
PCPT-RC but not of the ProstateCheck-RC.9,10 Strobl and colleagues found that recalibration 
according to local cohort characteristics can improve the performance of a static RC, that was 
originally designed as a one-size-fits all model.23 However, our data indicates that 
recalibration cannot be evaded by the use of a regional RC.  
The ProstateCheck-RC includes the variable TRUS-measured prostate volume. 
Interobserver variability of TRUS volume measurement can affect RC performance for 
an individual patient. Additionally, TRUS measurements are costly, invasive and 
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unpleasant. Therefore, to justify its implementation, the investigation must significantly raise 
the benefit of the RC compared to RCs that do not include this investigation. Our analysis 
shows that subtraction of potential harm of TRUS measurements significantly reduces the 
benefit of the RC resulting in superior benefit of the SWOP-RC and PCPT-RC. 
Free/total PSA ratio was not available in our dataset, which we consider the main limitation 
of this work. The missing variable might have an impact on the results of our validation. As 
the full details of the weight of different variables of the RC are not yet published, it remains 
unknown what the impact of this missing value is. Additionally prostate volumes for the 
SWOP-RC were not based on DRE but on TRUS measurements, which are known to be more 
accurate. This might lead to a better performance of the RC in the present investigation than 
expected if true DRE-based prostate volume was used. However, the performance of the 
PCPT-RC, which does not include prostate volume and thus had the most robust performance 
in our investigation, confirms the inferiority of the ProstateCheck-RC.  
Our results nicely illustrate that the ProstateCheck-RC does not have relevant benefit over the 
pre-existing and well-evaluated RCs. It seems that all RCs have limitations in contemporary 
patient cohorts due to the above-mentioned aspects. Thus, future research should rather focus 
on the development of RCs, which implement modern state of the art biopsy strategies and 
results from imaging studies such as multiparametric MRI 29 or novel biomarkers. The 
updated version of the SWOP RC including the Prostate Health Index (PHI) has recently been 
shown to be superior to the conventional SWOP-RC in an independent validation study.30 
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Conclusion 
Our independent, external evaluation revealed that the novel ProstateCheck-RC adds no 
benefit to PCa risk prediction compared to the PCPT or SWOP-RC. Future research should 
focus on RCs, which are based on contemporary clinical cohorts including novel tools such as 
biomarkers or results from imaging studies.  
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Figure legends 
 
Figure 1 and 2: Calibration plots for the ProstateCheck-RC predicting any prostate cancer (1) 
and high-grade prostate cancer (2). The x-axis shows predicted probabilities by the models 
and y-axis shows observed deciles. Deciles are shown by bullets with 95% Confidence 
intervals. 
 
Figure 3: Decision curve analysis of predicting high-grade prostate cancer on biopsy using 
the ProstateCheck-RC (green dashed line), the SWOP RC (black dashed line) and the PCPT 
RC (red dashed line). For the ProstateCheck-RC the net harm of TRUS measurements of 
prostate volume was incorporated into the decision curve. We assumed that a clinician would 
do no more than 50 TRUS to detect one high-grade PCa, even if TRUS were a perfect 
diagnostic test.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
